Discontinued
Avoparcin is a gram-positive glycopeptide antibiotic used in livestock feed for growth promotion in broiler chickens, growing pigs, calves and beef cattle. Avoparcin is also used as an aid in the prevention of necrotic enteritis in poultry.
Work plan
Work plan
Click on the tabs for more information about the status of each phase in the review process. For more information about how each phase is conducted, please read about the reconsideration process.
Chemicals
- Avoparcin
1. Nomination
1. Nomination
Phase status
CompletedAvoparcin is a gram-positive glycopeptide antibiotic used in livestock feed for growth promotion in broiler chickens, growing pigs, calves and beef cattle. Avoparcin is also used as an aid in the prevention of necrotic enteritis in poultry.
There are currently no registered products containing avoparcin in Australia.
2. Prioritisation
2. Prioritisation
Phase status
Completed
3. Scoping and work plan
3. Scoping and work plan
Phase status
Completed
4. Notice of reconsideration
4. Notice of reconsideration
Phase status
Completed
5. Assessment
5. Assessment
Phase status
Not requiredThe registrants did not renew the registration of their products after 30 June 2000 and voluntarily withdrew avoparcin from the market.
The APVMA completed the assessment of the residues data but did not continue with the review, as it was not likely to be completed before the withdrawal of avoparcin products from the market. The conclusions of the residues assessment are in the APVMA’s Avoparcin status document.
The APVMA will reactivate the review of avoparcin if the registrations of any products containing avoparcin are renewed. Any applicant interested in registering products containing avoparcin must provide data in accordance with the APVMA’s Manual of requirements and guidelines. Applicants must also provide a risk analysis of microbial resistance safety as outlined in the Guidelines for registering vet chemicals, Part 10, Special data requirements.
6. Proposed regulatory decision
6. Proposed regulatory decision
Phase status
Not required
7. Consultation
7. Consultation
Phase status
Not required
8. Final regulatory decision
8. Final regulatory decision
Phase status
Not required
9. Implementation
9. Implementation
Phase status
Not requiredIn 2006, the APVMA withdrew the maximum residue limit (MRL) for avoparcin.
Publication archive
Publication Archive
| Type | Title | Publication date |
|---|---|---|
| Gazette | Deletion of MRL | 3 Octobeer 2006 |
| Gazette | List of non-renewed registrations | 5 September 2000 |
| Report | Avoparcin status document | January 2001 |